Ultrasound-mediated nanobubble destruction (UMND), which can utilize the physical energy of ultrasound irradiation to improve the transfer efficiency to target cells is becoming one of the most promising carriers for gene delivery. The purpose of this study was to establish cell-penetrating peptide (CPP)-loaded nanobubbles (CNBs) connected with long intergenic nonprotein coding RNA 00511-small interfering RNA (LINC00511-siRNA) and evaluate its feasibility for improving the chemosensitivity of triple-negative...
Wed Aug 19, 2020 03:00
Dysregulation of microRNA contributes to multiple tumorigenic processes. Although downregulation of miR-199a-3p has been shown in many cancers, its effects on esophageal squamous cell carcinoma (ESCC) and the regulatory mechanism are still obscure. Here, we aim to evaluate the biological function and underlying mechanisms of miR-199a-3p in ESCC as well as its value to clinical treatment of ESCC. We first analyzed expression of miR-199a-3p in esophageal cancer by bioinformatic analysis and found that...
Wed Aug 19, 2020 03:00
Hyperammonemic encephalopathy represents a rare adverse effect of several chemotherapeutic agents, occurring in about 0.7% of patients treated with fluoropyrimidines, and it is independent from dihydropyrimidine dehydrogenase deficiency. Instead, its physiopathology is linked to the inhibition of Krebs cycle by fluoroacetate, leading to decreased ATP production, and to the inhibition of the urea cycle. Oxaliplatin seems to induce hyperammonemic encephalopathy in a similar way, acting on mitochondria....
Wed Aug 19, 2020 03:00
We aimed to investigate the expression level of long noncoding RNA (lncRNA) zinc finger E-box-binding homeobox two antisense RNA 1 (ZEB2-AS1) in osteosarcoma and explore its possible regulatory mechanisms. Expression of lncRNA ZEB2-AS1 was detected by quantitative real-time PCR in 63 cancerous tissues and 25 adjacent normal mucosal tissues from patients with osteosarcoma. The correlation between the lncRNA ZEB2-AS1 level and clinicopathological characteristics of the osteosarcoma patients were evaluated,...
Wed Aug 19, 2020 03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-01035-9Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies
03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-01029-7Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-1020-6T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-01031-zAlcohol drinking and head and neck cancer risk: the joint effect of intensity and duration
03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-01034-wOne-year mortality of colorectal cancer patients: development and validation of a prediction model using linked national electronic data
03:00
British Journal of Cancer, Published online: 24 August 2020; doi:10.1038/s41416-020-01036-8Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank
03:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Wed Aug 19, 2020 10:00
Abstract Aside from the induction of cell death, some anti‐cancer chemotherapeutic drugs can modulate antitumor immune responses. In this study, we examined the anti‐cancer effects of 5‐fluorouracil (5‐FU) and oxaliplatin (L‐OHP), which are standard chemotherapeutic drugs for colon cancer, combined with cyclophosphamide (CP) in two mouse colon cancer models (CT26 and MC38 colon adenocarcinoma models). In the CT26 model, two injections of 5‐FU/L‐OHP and CP significantly suppressed the growth of subcutaneously...
Thu Aug 20, 2020 17:53
Abstract Low‐dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid‐type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30mg/m2) + VBL (6mg/m2). Efficacy,...
Thu Aug 20, 2020 17:24
Abstract Glioblastoma, also known as glioblastoma multiforme (GBM), is a fast‐growing tumor and the most aggressive brain malignancy. Proteasome subunit beta type‐8 (PSMB8) is one of the 17 essential subunits for the complete assembly of the 20S proteasome complex. The aim of this study was to evaluate the role of PSMB8 expression in GBM progression and angiogenesis. PSMB8 expression in glioblastoma LN229 and U87MG were knockdown by siRNA or inducible shRNA both in vitro and in vivo. After PSMB8...
Thu Aug 20, 2020 16:18
Publication date: Available online 21 August 2020Source: Cancer/RadiothérapieAuthor(s): Y. Belkacemi, K. Debbi, G. Loganadane, S. Ghith, A. Hadhri, W. Hassani, M.A. Cherif, G. Coraggio, N.H. To, L. Colson-Durand, N. Grellier
Sat Aug 22, 2020 17:44
Publication date: Available online 21 August 2020Source: Cancer/RadiothérapieAuthor(s): A. Mège, J. Biau, E. Meyer, N. Allouache, M. Guigo, S. Servagi Vernat
Sat Aug 22, 2020 17:44
Publication date: Available online 21 August 2020Source: Cancer/RadiothérapieAuthor(s): S. Corbin, G. Brusadin, S. Rivera, A. Bossi, É. Deutsch
Sat Aug 22, 2020 17:44
Publication date: Available online 20 August 2020Source: Cancer/RadiothérapieAuthor(s): P. Giraud, D. Lerouge, I. Latorzeff, X. Mirabel, A. Dohan, P. Mordant, N. Barry de Longchamps
Fri Aug 21, 2020 18:03
Publication date: Available online 20 August 2020Source: Cancer/RadiothérapieAuthor(s): Y. Kirova, A. Tallet, M.C. Aznar, P. Loap, A. Bouali, C. Bourgier
Fri Aug 21, 2020 18:03
A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD disease phenotype, with 24 parameters changed between diseases. Modular nature of the model allows for easy incorporation of new mechanisms or modification of existing interactions. Model simulations for...
Fri Aug 21, 2020 16:45
Inflammatory bowel disease (IBD) is a heterogeneic disease with a variety of treatments targeting different mechanisms. A multistate, mechanistic, mathematical model of IBD was developed in part 1 of this two‐part article series. In this paper, application of the model to predict response of key clinical biomarkers following different treatment options for Crohn’s disease was explored. Five therapies, representing four different mechanisms of action, were simulated in the model and longitudinal profiles...
Fri Aug 21, 2020 16:44
Purpose: The recent approval of anti-PD-L1 immunotherapy in combination with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of chemotherapy in modulating the tumor-immune microenvironment (TIME). Experimental Design: We examined immune-related gene expression patterns before and after neoadjuvant chemotherapy (NAC) in a series of 83 breast tumors, including 44 TNBCs, from patients with residual disease (RD). Changes in gene expression...
Fri Aug 21, 2020 16:13
Purpose: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells. In this study, we evaluated if KPT-8602 would synergize with dexamethasone, vincristine or doxorubicin, three drugs currently used for the treatment of ALL. Experimental design: First, we searched for the most synergistic combination of KPT-8602 with dexamethasone, vincristine or doxorubicin...
Fri Aug 21, 2020 16:13
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): A.J.P. Clover, F. de Terlizzi, G. Bertino, P. Curatolo, J. Odili, L.G. Campana, C. Kunte, T. Muir, M. Brizio, G. Sersa, R. Pritchard Jones, G. Moir, A. Orlando, S.M. Banerjee, E. Kis, J.A. McCaul, E.M. Grischke, P. Matteucci, D. Mowatt, F.G. Bechara
Sat Aug 22, 2020 16:48
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Andrew R. Exley, Khadija Rantell, James McBlane
Sat Aug 22, 2020 16:48
Publication date: Available online 21 August 2020Source: European Journal of CancerAuthor(s): Jason Sicklick, Shumei Kato, Razelle Kurzrock
Sat Aug 22, 2020 16:48
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Pablo Nenclares, Derfel Ap Dafydd, Izhar Bagwan, Donna Begg, Cyrus Kerawala, Emma King, Ken Lingley, Vinidh Paleri, Gillian Paterson, Miranda Payne, Priyamal Silva, Neil Steven, Nancy Turnbull, Kent Yip, Kevin J. Harrington
Fri Aug 21, 2020 13:13
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Hsiang-Lin Tsai, Ching-Wen Huang, Yi-Wen Lin, Jui-Ho Wang, Chang-Chieh Wu, Yung-Chuan Sung, Tzu-Liang Chen, Hwei-Ming Wang, Hsiu-Chin Tang, Joe-Bin Chen, Tao-Wei Ke, Chang-Sung Tsai, Hsuan-Yuan Huang, Jaw-Yuan Wang
Fri Aug 21, 2020 13:13
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου